The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.
DNA Damage-Mediated Induction of a Chemoresistant Niche
Open accessAbstract
While numerous cell-intrinsic processes are known to play decisive roles in chemotherapeutic response, relatively little is known about the impact of the tumor microenvironment on therapeutic outcome. Here, we use a well-established mouse model of Burkitt's lymphoma to show that paracrine factors in the tumor microenvironment modulate lymphoma cell survival following the administration of genotoxic chemotherapy. Specifically, IL-6 and Timp-1 are released in the thymus in response to DNA damage, creating a "chemo-resistant niche" that promotes the survival of a minimal residual tumor burden and serves as a reservoir for eventual tumor relapse. Notably, IL-6 is released acutely from thymic endothelial cells in a p38-dependent manner following genotoxic stress, and this acute secretory response precedes the gradual induction of senescence in tumor-associated stromal cells. Thus, conventional chemotherapies can induce tumor regression while simultaneously eliciting stress responses that protect subsets of tumor cells in select anatomical locations from drug action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These chemoprotective SASP factors include WNT16B, IL-6, and TIMP-1 (tissue inhibitor of metalloproteinases-1).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [134]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even more ironic is the finding that senescent cells, particularly those that senesce in response to DNA-damaging radiation or chemotherapeutic agents, secrete factors that can protect neighboring tumor cells from being killed by those same chemotherapeutic agents (133, 134).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [134]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antibody against IL-6, gp130 siRNA, or dominant-negative STAT3 enhanced chemo-induced death in lymphoma (Gilbert and Hemann, 2010), as well as colon cancer (Yun et al., 2012)”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Gilbert and Hemann, 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-6 and pY-STAT3 induced by chemotherapy promoted premature senescence in lymphoma cells in a paracrine manner, which maintained a minimal residual number of chemoresistant cells that could lead to relapse.”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Gilbert and Hemann, 2010
Experimental — accuracy not yet measuredIn the citing paper
“Recent evidence points to tumor microenvironment components as potential participants in the generation of chemoresistance (Denardo et al., 2011; Gilbert and Hemann, 2010; Roodhart et al., 2011; Shaked et al., 2008; Shree et al., 2011).”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Gilbert and Hemann, 2010
In the citing paper
“Recent reports (Denardo et al., 2011; Gilbert and Hemann, 2010) and the present work show that chemotherapy induces a storm of cytokines and chemokines in the tumor microenvironment many of which might be linked to chemoresistance.”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Gilbert and Hemann, 2010
In the citing paper
“The critical role of the microenvironment in tumor progression and response to therapy is being increasingly recognized (Condeelis and Pollard, 2006; Denardo et al., 2011; Gilbert and Hemann, 2010; Shree et al., 2011; Tan et al., 2011).”
From A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis (2012) · cites this paper as Gilbert and Hemann, 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
Visvader, J. E., & Lindeman, G. J. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2499 · Cited by 3,501
Metastasis: from dissemination to organ-specific colonization
Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2622 · Cited by 2,716
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027
Flagged first, then by citations
2 of the 42 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Emerging Biological Principles of Metastasis
Lambert, A. W., Pattabiraman, D. R., & Weinberg, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.11.037 · Cited by 3,191
Aging, Cellular Senescence, and Cancer
Campisi, J. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183653 · Cited by 2,954
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Metastatic colonization by circulating tumour cells
Massagué, J., & Obenauf, A. C. (2016) · Nature · doi:10.1038/nature17038 · Cited by 2,062
Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype
Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy
Mehta, G., Hsiao, A. Y., Ingram, M., Luker, G. D., & Takayama, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.045 · Cited by 1,172
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.042 · Cited by 1,085
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S. R., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,132
Unmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863
Sun, Y., Campisi, J., Higano, C., Beer, T. M., Porter, P., Coleman, I., True, L., & Nelson, P. S. (2012) · Nature Medicine · doi:10.1038/nm.2890 · Cited by 793
Microenvironmental regulation of therapeutic response in cancer
Klemm, F., & Joyce, J. A. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.11.006 · Cited by 795
Tumor metastasis: moving new biological insights into the clinic
Wan, L., Pantel, K., & Kang, Y. (2013) · Nature Medicine · doi:10.1038/nm.3391 · Cited by 763
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 758
New horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704
Moiseeva, O., Deschênes‐Simard, X., St‐Germain, E., Igelmann, S., Huot, G., Cadar, A. E., Bourdeau, V., Pollak, M. N., & Ferbeyre, G. (2013) · Aging Cell · doi:10.1111/acel.12075 · Cited by 654
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Domańska, U., Kruizinga, R. C., Nagengast, W. B., Timmer‐Bosscha, H., Huls, G. A., de Vries, E. G. E., & Walenkamp, A. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.005 · Cited by 659
The senescence-associated secretory phenotype and its regulation
Lopes-Paciencia, S., Saint-Germain, E., Rowell, M.-C., Ruiz, A. F., Kalegari, P., & Ferbeyre, G. (2019) · Cytokine · doi:10.1016/j.cyto.2019.01.013 · Cited by 601
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M. R., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 485
Kuczynski, E. A., Vermeulen, P. B., Pezzella, F., Kerbel, R. S., & Reynolds, A. R. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0181-9 · Cited by 457
Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging
Thomas, R., Wang, W., & Su, D.-M. (2020) · Immunity & Ageing · doi:10.1186/s12979-020-0173-8 · Cited by 442
Heterogeneity Maintenance in Glioblastoma: A Social Network
Bonavia, R., Inda, M.-D.-M., Cavenee, W. K., & Furnari, F. B. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0153 · Cited by 441
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 446
Tumor Microenvironment and Differential Responses to Therapy
Hirata, E., & Sahai, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026781 · Cited by 422
Versatile functions for IL-6 in metabolism and cancer
Mauer, J., Denson, J. L., & Brüning, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.008 · Cited by 415
Tumor microenvironment and cancer therapy resistance
Sun, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.044 · Cited by 391
Telomerase directly regulates NF-κB-dependent transcription
Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., Wong, M., Zhang, Z., Li, G., Sung, W.-K., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2621 · Cited by 378
On the dual roles and polarized phenotypes of neutrophils in tumor development and progression
Piccard, H., Muschel, R. J., & Opdenakker, G. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.06.004 · Cited by 369
Elucidating Compound Mechanism of Action by Network Perturbation Analysis
Woo, J. H., Shimoni, Y., Yang, W. S., Subramaniam, P., Iyer, A., Nicoletti, P., Rodríguez Martínez, M., López, G., Mattioli, M., Realubit, R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.056 · Cited by 351
Hyperprogressive disease: recognizing a novel pattern to improve patient management
Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 366
Lotti, F., Jarrar, A., Pai, R. K., Hitomi, M., Lathia, J. D., Mace, A. G., Gantt, G., Sukhdeo, K., DeVecchio, J., Vasanji, A., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131195 · Cited by 378
Récher, C., Coiffier, B., Haïoun, C., Molina, T. J., Fermé, C., Casasnovas, O., Thiéblemont, C., Bosly, A., Laurent, G., Morschhauser, F., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61040-4 · Cited by 354
Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
Distinctive properties of metastasis-initiating cellsPreprint
Celià-Terrassa, T., & Kang, Y. (2016) · Genes & Development · doi:10.1101/gad.277681.116 · Cited by 342
Kern, L., Mittenbühler, M., Vesting, A., Ostermann, A., Wunderlich, C., & Wunderlich, F. (2018) · Cancers · doi:10.3390/cancers11010024 · Cited by 331
Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314
“Antibody against IL-6, gp130 siRNA, or dominant-negative STAT3 enhanced chemo-induced death in lymphoma (Gilbert and Hemann, 2010), as well as colon cancer (Yun et al., 2012), indicating that targeting IL-6/STAT3 signaling may be a viable strategy for bypassing senescence-induced chemoresistance.”
BackgroundOhtani, N. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00197-8 · Cited by 329
Hu, K., Miao, L., Goodwin, T. J., Li, J., Liu, Q., & Huang, L. (2017) · ACS Nano · doi:10.1021/acsnano.7b01522 · Cited by 293
Extracellular matrix components in breast cancer progression and metastasis
Óskarsson, T. (2013) · The Breast · doi:10.1016/j.breast.2013.07.012 · Cited by 304
Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing
McFadden, D. G., Papagiannakopoulos, T. Y., Taylor-Weiner, A. N., Stewart, C., Carter, S. L., Cibulskis, K., Bhutkar, A. J., McKenna, A., Dooley, A. L., Vernon, A. N., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.031 · Cited by 284
Nuclear genomic instability and aging
Niedernhofer, L. J., Gurkar, A. U., Wang, Y., Vijg, J., Hoeijmakers, J. H. J., & Robbins, P. D. (2018) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-012239 · Cited by 275
Gafita, A., Calais, J., Grogan, T. R., Hadaschik, B., Wang, H., Weber, M., Sandhu, S., Kratochwil, C., Esfandiari, R., Tauber, R., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00274-6 · Cited by 271
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?
Hölzel, M., Bovier, A., & Tüting, T. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3498 · Cited by 275
Özeş, A., Miller, D. F., Özeş, O. N., Fang, F., Liu, Y., Matei, D. E., Huang, T. H. ‐., & Nephew, K. P. (2016) · Oncogene · doi:10.1038/onc.2016.75 · Cited by 271
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 260
Telomerase: central regulator of all of the hallmarks of cancer
Low, K. C., & Tergaonkar, V. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.07.001 · Cited by 265
Physiological and pathological consequences of cellular senescence
Burton, D. G. A., & Krizhanovsky, V. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1691-3 · Cited by 253
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 270
Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts
Laberge, R.-M., Awad, P., Campisi, J., & Desprez, P.-Y. (2012) · Cancer Microenvironment · doi:10.1007/s12307-011-0069-4 · Cited by 255
Cell Senescence: Role in Aging and Age-Related Diseases
Campisi, J., & Robert, L. (2014) · Interdisciplinary Topics in Gerontology and Geriatrics · doi:10.1159/000358899 · Cited by 240
Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy
Carlson, P., Dasgupta, A., Grzelak, C. A., Kim, J., Barrett, A. S., Coleman, I. M., Shor, R. E., Goddard, E. T., Dai, J., Schweitzer, E. M., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0267-0 · Cited by 248
Malaquin, N., Martinez, A., & Rodier, F. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.010 · Cited by 247
Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance
Taylor, T. E., Furnari, F. B., & Cavenee, W. K. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912799277557 · Cited by 247
Cao, Z., Ding, B., Guo, P., Lee, S. B., Butler, J. M., Casey, S. C., Simons, M., Tam, W., Felsher, D. W., Shido, K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.005 · Cited by 227
Circulating and disseminated tumor cells: harbingers or initiators of metastasis?
Dasgupta, A., Lim, A. R., & Ghajar, C. M. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12022 · Cited by 225
Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion
D’Alterio, C., Scala, S., Sozzi, G., Roz, L., & Bertolini, G. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.019 · Cited by 231
Roles of Matrix Metalloproteinases and Their Natural Inhibitors in Prostate Cancer Progression
Gong, Y., Chippada-Venkata, U., & Oh, W. K. (2014) · Cancers · doi:10.3390/cancers6031298 · Cited by 223
SASP: Tumor Suppressor or Promoter? Yes!
Rao, S. G., & Jackson, J. G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.001 · Cited by 206
Corre, I., Paris, F., & Huot, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18264 · Cited by 195
The multifaceted role of mesenchymal stem cells in cancer
Timaner, M., Tsai, K. K., & Shaked, Y. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.003 · Cited by 196
Targeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala‐Dilke, K., & Bergers, G. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 216
CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
Domańska, U., Timmer‐Bosscha, H., Nagengast, W. B., Munnink, T. H. O., Kruizinga, R. C., Ananias, H. J. K., Kliphuis, N. M., Huls, G. A., de Vries, E. G. E., de Jong, I. J., et al. (2012) · Neoplasia · doi:10.1593/neo.12324 · Cited by 196
Chang, C.-H., Hsiao, C.-F., Yeh, Y.-M., Chang, G., Tsai, Y.-H., Chen, Y.-M., Huang, M.-S., Chen, H.-L., Li, Y.-J., Yang, P.-C., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27892 · Cited by 187
Pathological roles of the homeostatic chemokine CXCL12
Janssens, R., Struyf, S., & Proost, P. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.004 · Cited by 187
The pro-tumorigenic host response to cancer therapies
Shaked, Y. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0209-6 · Cited by 185
Bunn, P. A., Minna, J. D., Augustyn, A., Gazdar, A. F., Ouadah, Y., Krasnow, M. A., Berns, A. J. M., Brambilla, E. M., Rekhtman, N., Massion, P. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.012 · Cited by 180
Bent, E. H., Gilbert, L. A., & Hemann, M. T. (2016) · Genes & Development · doi:10.1101/gad.284851.116 · Cited by 179
Self-citationp38MAPK plays a crucial role in stromal-mediated tumorigenesis
Alspach, E., Flanagan, K. C., Luo, X., Ruhland, M. K., Huang, H., Pazolli, E., Donlin, M. J., Marsh, T., Piwnica-Worms, D., Monahan, J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0743 · Cited by 167
Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities
Porter, D. C., Farmaki, E., Altilia, S., Schools, G. P., West, D. K., Chen, M., Chang, B.-D., Puzyrev, A. T., Lim, C., Rokow-Kittell, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206906109 · Cited by 177
Cellular senescence and the tumour microenvironment
Takasugi, M., Yoshida, Y., & Ohtani, N. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13268 · Cited by 190
IL-6-STAT3 signaling and premature senescence
Kojima, H., Inoue, T., Kunimoto, H., & Nakajima, K. (2013) · JAK-STAT · doi:10.4161/jkst.25763 · Cited by 170
Zhou, Y., Wan, G., Spizzo, R., Ivan, C., Mathur, R., Hu, X., Ye, X., Lu, J., Fan, F., Xia, L., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.09.004 · Cited by 171
CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy
Mousavi, A. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.11.007 · Cited by 171
Stromal Endothelial Cells Directly Influence Cancer Progression
Franses, J. W., Baker, A. B., Chitalia, V. C., & Edelman, E. R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001542 · Cited by 170
Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 168
Chambers, C. R., Ritchie, S., Pereira, B., & Timpson, P. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13042 · Cited by 182
Yasuda, T., Koiwa, M., Yonemura, A., Miyake, K., Kariya, R., Kubota, S., Yokomizo-Nakano, T., Yasuda-Yoshihara, N., Uchihara, T., Itoyama, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108779 · Cited by 165
Garcia‐Manero, G., Tambaro, F. P., Bekele, N. B., Yang, H., Ravandi, F., Jabbour, E. J., Borthakur, G. M., Kadia, T. M., Konopleva, M. Y., Faderl, S. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3265 · Cited by 166
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163
Muñoz, D. P., Yannone, S. M., Daemen, A., Sun, Y., Vakar-Lopez, F., Kawahara, M., Freund, A. M., Rodier, F., Wu, J. D., Desprez, P.-Y., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124716 · Cited by 162
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence
Madden, E. C., Gorman, A. M., Logue, S. E., & Samali, A. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.020 · Cited by 161
Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy
Bent, E. H., Millán-Barea, L. R., Zhuang, I., Goulet, D. R., Fröse, J., & Hemann, M. T. (2021) · Nature Communications · doi:10.1038/s41467-021-26407-4 · Cited by 167
Self-citationZhang, B., Fu, D., Xu, Q., Cong, X., Wu, C., Zhong, X., Ma, Y., Lv, Z., Chen, F., Han, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04010-4 · Cited by 157
Cancer invasion and resistance: interconnected processes of disease progression and therapy failure
Alexander, S., & Friedl, P. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.11.003 · Cited by 159
Design of nanocarriers based on complex biological barriers in vivo for tumor therapy
Liu, J., Li, M., Luo, Z. Y., Dai, L., Guo, X., & Cai, K. (2017) · Nano Today · doi:10.1016/j.nantod.2017.06.010 · Cited by 158
Chang, Y. S., Jalgaonkar, S. P., Middleton, J. D., & Hai, T. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700455114 · Cited by 157
Tumor cell–organized fibronectin maintenance of a dormant breast cancer population
Barney, L. E., Hall, C. L., Schwartz, A. D., Parks, A. N., Sparages, C., Galarza, S., Platt, M. O., Mercurio, A. M., & Peyton, S. R. (2020) · Science Advances · doi:10.1126/sciadv.aaz4157 · Cited by 161
Sugimura, K., Miyata, H., Tanaka, K., Hamano, R., Takahashi, T., Kurokawa, Y., Yamasaki, M., Nakajima, K., Takiguchi, S., Mori, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0701 · Cited by 155
Molecular Mechanisms of Cancer-Induced Sleep Disruption
Walker, W. H., II, & Borniger, J. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112780 · Cited by 149
The role of cellular senescence in skin aging and age-related skin pathologies
Chin, T., Lee, X. E., Ng, P. Y., Lee, Y., & Dreesen, O. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1297637 · Cited by 164
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody
Zhang, S., Zhang, H., Ghia, E. M., Huang, J., Wu, L., Zhang, J., Lam, S., Yang, L., He, J., Cui, B., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816262116 · Cited by 143
Fibroblast-mediated drug resistance in cancer
Paraiso, K. H. T., & Smalley, K. S. M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.018 · Cited by 147
Metadata
- Authors
- Gilbert, L. A., & Hemann, M. T.
- Affiliations
- Koch Institute for Integrative Cancer Research At MIT (US)
- Corresponding author
- Hemann, Michael T.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 143
- Issue
- 3
- Pages
- 355-366
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC2972353
- OpenAlex
- W2124472585
- Cited by
- 428
- References
- 42
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 12 · 2023: 19 · 2022: 32 · 2021: 35 · 2020: 27 · 2019: 37 · 2018: 33 · 2017: 26 · 2016: 29 · 2015: 25 · 2014: 25 · 2013: 40 · 2012: 40
- FWCI
- 22.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1056 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Elsevier eBooks
- Funders
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (5r01ca128803-05)
- Ludwig Center for Molecular Oncology
- National Cancer Institute (R01-CA128803)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- chemoresistance, tumor microenvironment, DNA damage, Burkitt lymphoma, interleukin-6, TIMP-1, thymus, p38 MAPK, genotoxic stress response, senescence, tumor stromal cells, minimal residual disease, tumor recurrence, paracrine signaling
- MeSH terms
- Animals, Burkitt Lymphoma, Cell Survival, DNA Damage, Doxorubicin, Humans, Liver Neoplasms, Thymus Gland, Interleukin-6, Cytokines, Cellular Senescence, Culture Media, Conditioned, Neoplasm, Residual, Cell Culture Techniques, Drug Resistance, Neoplasm, Tissue Inhibitor of Metalloproteinase-1, Paracrine Communication, Endothelial Cells, p38 Mitogen-Activated Protein Kinases, Mice, Janus Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
